Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in Diabetes and the Metabolic Syndrome

Heinl, Robert E.; Dhindsa, Devinder S.; Mahlof, Elliot N.; Schultz, William W.; Ricketts, John C.; Varghese, Tina; Esmaeeli, A; Allard-Ratick, Marc; Millard, Anthony J.; Kelli, Heval Mohamed; Sandesara, Pratik B.; Eapen, Danny J.; Sperling, Laurence

doi:10.1016/j.cjca.2016.07.507

Cited by 16 publications

(10 citation statements)

References 92 publications

(111 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The epidemic of obesity has contributed to a growing burden of CVD risk factors such as T2DM and MetS [ 37 ] (defined as the presence of at least 3 out of the 4 criteria: central obesity, increased blood pressure, high blood sugar levels, and dyslipidemia [ 38 ]). Dyslipidemia is a well-established modifiable cardiovascular risk factor.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials

Qin

Huang

Gong

et al. 2017

Nutr J

180

117

View full text Add to dashboard Cite

BackgroundDyslipidemia is an important and common cardiovascular risk factor in the general population. The lipid-lowering effects of turmeric and curcumin are unconfirmed. We performed a meta-analysis to assess the efficacy and safety of turmeric and curcumin in lowering blood lipids in patients at risk of cardiovascular disease (CVD).MethodsA comprehensive literature search was conducted on PubMed, Embase, Ovid, Medline and Cochrane Library databases to identify randomized controlled trials (published as of November 2016) that assessed the effect of turmeric and curcumin on blood lipid levels including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Pooled standardized mean difference (SMD) with 95% confidence interval (CI) was used to assess the effect.ResultsThe analysis included 7 eligible studies (649 patients). Turmeric and curcumin significantly reduced serum LDL-C (SMD = −0.340, 95% confidence interval [CI]: −0.530 to −0.150, P < 0.0001) and TG (SMD = −0.214, 95% CI: −0.369 to −0.059, P = 0.007) levels as compared to those in the control group. These may be effective in lowering serum TC levels in patients with metabolic syndrome (MetS, SMD = −0.934, 95% CI: −1.289 to −0.579, P < 0.0001), and turmeric extract could possibly have a greater effect on reducing serum TC levels (SMD = −0.584, 95% CI: −0.980 to −0.188, P = 0.004); however, the efficacy is yet to be confirmed. Serum HDL-C levels were not obviously improved. Turmeric and curcumin appeared safe, and no serious adverse events were reported in any of the included studies.ConclusionsTurmeric and curcumin may protect patients at risk of CVD through improving serum lipid levels. Curcumin may be used as a well-tolerated dietary adjunct to conventional drugs. Further research is required to resolve uncertainties related to dosage form, dose and medication frequency of curcumin.Electronic supplementary materialThe online version of this article (10.1186/s12937-017-0293-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials

Qin

Huang

Gong

et al. 2017

Nutr J

180

117

View full text Add to dashboard Cite

show abstract

“…Obesity is a multifactorial disease, characterized by a local and systemic chronic low-grade inflammatory state causing metabolic abnormalities and adipocyte dysfunction [ 54 ], that ultimately leads to CVD. This state has also been implicated in the development of obesity-related comorbidities [ 55 ], and the growing MS prevalence seems to be closely related to the obesity epidemic [ 56 ]. Additionally, obesity also seems to be associated with the rising prevalence of dyslipidemia, as several studies have suggested a positive correlation between body mass index (BMI) and dyslipidemia [ 57 , 58 ].…”

Section: Obesity and Dyslipidemia: Two Disorders Walking Togethermentioning

confidence: 99%

Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue

Dias

Paredes

Ribeiro

2018

International Journal of Endocrinology

View full text Add to dashboard Cite

Metabolic syndrome can be defined as a state of disturbed metabolic homeostasis characterized by visceral obesity, atherogenic dyslipidemia, arterial hypertension, and insulin resistance. The growing prevalence of metabolic syndrome will certainly contribute to the burden of cardiovascular disease. Obesity and dyslipidemia are main features of metabolic syndrome, and both can present with adipose tissue dysfunction, involved in the pathogenic mechanisms underlying this syndrome. We revised the effects, and underlying mechanisms, of the current approved drugs for dyslipidemia and obesity (fibrates, statins, niacin, resins, ezetimibe, and orlistat; sibutramine; and diethylpropion, phentermine/topiramate, bupropion and naltrexone, and liraglutide) on adipose tissue. Specifically, we explored how these drugs can modulate the complex pathways involved in metabolism, inflammation, atherogenesis, insulin sensitivity, and adipogenesis. The clinical outcomes of adipose tissue modulation by these drugs, as well as differences of major importance for clinical practice between drugs of the same class, were identified. Whether solutions to these issues will be found in further adjustments and combinations between drugs already in use or necessarily in new advances in pharmacology is not known. To better understand the effect of drugs used in dyslipidemia and obesity on adipose tissue not only is challenging for physicians but could also be the next step to tackle cardiovascular disease.

show abstract

“…MetS is a risk factor of cardiovascular and metabolic complications; which is associated with several medical conditions such as type 2 diabetes, cardiovascular diseases, and nonalcoholic fatty liver disease. 1 , 2 , 3 …”

Section: Metabolism Metabolic Syndrome and Prostate Healthmentioning

confidence: 99%

Looking to the metabolic landscapes for prostate health monitoring

Kim

2017

Prostate International

View full text Add to dashboard Cite

Abnormal metabolism is a widely accepted biological signature of prostatic diseases, including prostate cancer and benign prostate hyperplasia. Recently accumulated epidemiological and experimental evidence illustrate that the metabolic syndrome, impaired mitochondrial function, and prostatic pathological conditions intersect. The perturbed metabolism and metabolic mediates influence key signaling pathways in various prostatic pathological conditions. This short review article aids to highlight recent findings on metabolism, metabolic mechanisms, and mitochondrial metabolism as a possible route to finding a cure for prostate diseases, including prostate cancer. The effort to better understand the role that mitochondria plays in cancer metabolism and the biological meaning of defective and/or deleted mitochondrial DNA in cancer will also be discussed.

show abstract

Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in Diabetes and the Metabolic Syndrome

Cited by 16 publications

References 92 publications

Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials

Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials

Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue

Looking to the metabolic landscapes for prostate health monitoring

Contact Info

Product

Resources

About